{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:11:53Z","timestamp":1765609913380,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12325-019-00946-1","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T19:02:57Z","timestamp":1555700577000},"page":"1337-1357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs"],"prefix":"10.1007","volume":"36","author":[{"given":"Noemi","family":"Muszbek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-I","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kuznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsofia","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaleb","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"946_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"946_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11926-010-0117-y","volume":"12","author":"E Myasoedova","year":"2010","unstructured":"Myasoedova E, Davis JM 3rd, Crowson CS, et al. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12:379\u201385.","journal-title":"Curr Rheumatol Rep"},{"key":"946_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.15585\/mmwr.mm6609e1","volume":"66","author":"KE Barbour","year":"2017","unstructured":"Barbour KE, Helmick CG, Boring M, et al. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation\u2014United States, 2013\u20132015. MMWR Morb Mortal Wkly Rep. 2017;66:246\u201353.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"946_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1185\/03007990903422307","volume":"26","author":"H Birnbaum","year":"2010","unstructured":"Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26:77\u201390.","journal-title":"Curr Med Res Opin"},{"key":"946_CR5","volume-title":"Harrison\u2019s principles of internal medicine","author":"A Shah","year":"2015","unstructured":"Shah A, St Clair W. Rheumatoid arthritis. In: Kasper D, Fauci A, Hauser S, et al., editors. Harrison\u2019s principles of internal medicine. 19th ed. New York: McGraw-Hill Education; 2015.","edition":"19"},{"key":"946_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3899\/jrheum.100589","volume":"38","author":"A Beresniak","year":"2011","unstructured":"Beresniak A, Gossec L, Goupille P, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol. 2011;38:439\u201345.","journal-title":"J Rheumatol"},{"key":"946_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-017-1293-1","volume":"19","author":"M Grabner","year":"2017","unstructured":"Grabner M, Boytsov NN, Huang Q, et al. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Res Ther. 2017;19:92.","journal-title":"Arthritis Res Ther."},{"key":"946_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis"},{"key":"946_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68:1\u201325.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"946_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"946_CR11","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424\u201337.","journal-title":"Arthritis Rheumatol."},{"key":"946_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis. 2016;75:68\u201374.","journal-title":"Ann Rheum Dis"},{"key":"946_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","volume":"18","author":"V Strand","year":"2016","unstructured":"Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.","journal-title":"Arthritis Res Ther."},{"key":"946_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69:277\u201390.","journal-title":"Arthritis Rheumatol."},{"key":"946_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"946_CR16","unstructured":"Davis S, Stevenson M, Tappenden P, et al. Cost-Effectiveness Modelling Using Patient-Level Simulation [Internet]. London: National Institute for Health and Care Excellence (NICE); 2014. NICE DSU Technical Support Document No. 15. 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310370\/ . Accessed 13 Nov 2017."},{"key":"946_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0049-0172(97)80012-1","volume":"27","author":"AM Abdel-Nasser","year":"1997","unstructured":"Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum. 1997;27:123\u201340.","journal-title":"Semin Arthritis Rheum"},{"key":"946_CR18","unstructured":"Institute for Clinical and Economic Review. Targeted immune modulators for rheumatoid arthritis: effectiveness and value. Evidence report. 2017. https:\/\/icer-review.org\/wp-content\/uploads\/2016\/08\/NE_CEPAC_RA_Evidence_Report_FINAL_040717.pdf . Accessed 28 Sept 2017."},{"key":"946_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Mak. 2012;32:667\u201377.","journal-title":"Med Decis Mak"},{"key":"946_CR20","first-page":"S75","volume":"23","author":"T Huynh","year":"2017","unstructured":"Huynh T, Proudfoot C, Chen C, et al. Network meta-analysis of the efficacy and safety of sarilumab monotherapy and combination therapy in rheumatoid arthritis patients with intolerance or inadequate response to disease-modifying antirheumatic drugs. J Manag Care Spec Pharm. 2017;23:S75.","journal-title":"J Manag Care Spec Pharm."},{"key":"946_CR21","first-page":"1","volume":"20","author":"M Stevenson","year":"2016","unstructured":"Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20:1\u2013610.","journal-title":"Health Technol Assess"},{"key":"946_CR22","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23:S14\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"946_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1\u2013278.","journal-title":"Health Technol Assess"},{"key":"946_CR24","unstructured":"National Institute for Health and Care Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, NICE technology appraisal guidance [TA130]. 2007. https:\/\/www.nice.org.uk\/guidance\/ta130 . Accessed 21 Oct 2017."},{"key":"946_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/ard.2004.027565","volume":"64","author":"NJ Bansback","year":"2005","unstructured":"Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64:995\u20131002.","journal-title":"Ann Rheum Dis"},{"key":"946_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1098-3015(10)61216-8","volume":"5","author":"R Boggs","year":"2002","unstructured":"Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (D2E7). Value in Health. 2002;5:452\u20133.","journal-title":"Value in Health."},{"key":"946_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3899\/jrheum.110491","volume":"39","author":"K Michaud","year":"2012","unstructured":"Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol. 2012;39:54\u20139.","journal-title":"J Rheumatol"},{"key":"946_CR28","first-page":"1","volume":"64","author":"E Arias","year":"2015","unstructured":"Arias E. United States Life Tables, 2011. Natl Vital Stat Rep. 2015;64:1\u201363.","journal-title":"Natl Vital Stat Rep."},{"key":"946_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jclinepi.2006.09.006","volume":"60","author":"CA Marra","year":"2007","unstructured":"Marra CA, Marion SA, Guh DP, et al. Not all \u201cquality-adjusted life years\u201d are equal. J Clin Epidemiol. 2007;60:616\u201324.","journal-title":"J Clin Epidemiol"},{"key":"946_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3111\/13696998.2012.665110","volume":"15","author":"A Diamantopoulos","year":"2012","unstructured":"Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15:576\u201385.","journal-title":"J Med Econ."},{"key":"946_CR31","unstructured":"Wailoo A, Brennan A, Bansback N, et al. Modeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare program. 2006. http:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Reports\/Research-Reports-Items\/CMS1202288.html . Accessed 13 Nov 2017."},{"key":"946_CR32","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996."},{"key":"946_CR33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"GC Fonarow","year":"2017","unstructured":"Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069\u201378.","journal-title":"JAMA Cardiol."},{"key":"946_CR34","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","volume":"63","author":"JL Anderson","year":"2014","unstructured":"Anderson JL, Heidenreich PA, Barnett PG, et al. ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2304\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"946_CR35","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006."},{"key":"946_CR36","unstructured":"World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis 2003. http:\/\/www.who.int\/choice\/publications\/p_2003_generalised_cea.pdf . Accessed 13 Nov 2017."},{"key":"946_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Org. 2015;93:118\u201324.","journal-title":"Bull World Health Org"},{"key":"946_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3111\/13696998.2014.1001848","volume":"18","author":"ML Ganz","year":"2015","unstructured":"Ganz ML, Hansen BB, Valencia X, et al. Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. J Med Econ. 2015;18:366\u201375.","journal-title":"J Med Econ."},{"issue":"Suppl 4","key":"946_CR39","doi-asserted-by":"publisher","first-page":"iv32","DOI":"10.1093\/rheumatology\/ker244","volume":"50","author":"P Barton","year":"2011","unstructured":"Barton P. Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans. Rheumatology (Oxford). 2011;50(Suppl 4):iv32\u20138.","journal-title":"Rheumatology (Oxford)."},{"key":"946_CR40","unstructured":"National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. Technology appraisal guidance [TA195]. 2010. https:\/\/www.nice.org.uk\/guidance\/ta195 . Accessed 28 Sept 2017."},{"issue":"Suppl 4","key":"946_CR41","doi-asserted-by":"publisher","first-page":"iv26","DOI":"10.1093\/rheumatology\/ker243","volume":"50","author":"J Tosh","year":"2011","unstructured":"Tosh J, Brennan A, Wailoo A, et al. The Sheffield rheumatoid arthritis health economic model. Rheumatology (Oxford). 2011;50(Suppl 4):iv26\u201331.","journal-title":"Rheumatology (Oxford)."},{"key":"946_CR42","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, et al. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53:1664\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"946_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","volume":"20","author":"B Chastek","year":"2017","unstructured":"Chastek B, Becker LK, Chen CI, et al. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ. 2017;20:464\u201373.","journal-title":"J Med Econ."},{"key":"946_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR good research practices task force report. Value Health. 2015;18:161\u201372.","journal-title":"Value Health."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00946-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T03:28:39Z","timestamp":1721186919000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00946-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00946-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2019,4,19]]},"assertion":[{"value":"8 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}